Review article

2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy

M. H. Miller (Lead / Corresponding author), K. Agarwal, A. Austin, A. Brown, S. T. Barclay, P. Dundas, G. M. Dusheiko, G. R. Foster, R. Fox, P. C. Hayes, C. Leen, C. Millson, S. D. Ryder, J. Tait, A. Ustianowski, J. F. Dillon

    Research output: Contribution to journalArticle

    33 Citations (Scopus)

    Abstract

    Background: Therapeutic options for the management of hepatitis C virus (HCV) infection have evolved rapidly over the past two decades, with a consequent improvement in cure rates. Novel therapeutic agents are an area of great interest in the research community, with a number of these agents showing promise in the clinical setting. Aims: To assess and present the available evidence for the use of novel therapeutic agents for the treatment of HCV, updating previous guidelines. Methods: All Phase 2 and 3 studies, as well as abstract presentations from international Hepatology meetings were identified and reviewed for suitable inclusion, based on studies of new therapies in HCV. Treatment-naïve and experienced individuals, as well as cirrhotic and co-infected individuals were included. Results: Sofosbuvir, simeprevir and faldaprevir, along with pegylated interferon and ribavirin, have a role in the treatment of chronic HCV infection. The precise regimens are largely dependent on the patient characteristics, patient and physician preferences, and cost implication. Conclusions: Therapies for chronic HCV have evolved dramatically in recent years. Interferon-free regimens are now possible without compromise in the rate of sustained viral response. The decision as to which regimen is most appropriate is multifactorial, and based on efficacy, safety and cost.
    Original languageEnglish
    Pages (from-to)1363-1375
    Number of pages13
    JournalAlimentary Pharmacology & Therapeutics
    Volume39
    Issue number12
    DOIs
    Publication statusPublished - Jun 2014

    Fingerprint

    Hepatitis C
    Guidelines
    Hepacivirus
    Chronic Hepatitis C
    Virus Diseases
    Interferons
    Therapeutics
    Costs and Cost Analysis
    Patient Preference
    Ribavirin
    Therapeutic Uses
    Gastroenterology
    Physicians
    Safety
    Research

    Cite this

    Miller, M. H. ; Agarwal, K. ; Austin, A. ; Brown, A. ; Barclay, S. T. ; Dundas, P. ; Dusheiko, G. M. ; Foster, G. R. ; Fox, R. ; Hayes, P. C. ; Leen, C. ; Millson, C. ; Ryder, S. D. ; Tait, J. ; Ustianowski, A. ; Dillon, J. F. / Review article : 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy. In: Alimentary Pharmacology & Therapeutics. 2014 ; Vol. 39, No. 12. pp. 1363-1375.
    @article{ea14facb7757480791fe0f96f371360b,
    title = "Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy",
    abstract = "Background: Therapeutic options for the management of hepatitis C virus (HCV) infection have evolved rapidly over the past two decades, with a consequent improvement in cure rates. Novel therapeutic agents are an area of great interest in the research community, with a number of these agents showing promise in the clinical setting. Aims: To assess and present the available evidence for the use of novel therapeutic agents for the treatment of HCV, updating previous guidelines. Methods: All Phase 2 and 3 studies, as well as abstract presentations from international Hepatology meetings were identified and reviewed for suitable inclusion, based on studies of new therapies in HCV. Treatment-na{\"i}ve and experienced individuals, as well as cirrhotic and co-infected individuals were included. Results: Sofosbuvir, simeprevir and faldaprevir, along with pegylated interferon and ribavirin, have a role in the treatment of chronic HCV infection. The precise regimens are largely dependent on the patient characteristics, patient and physician preferences, and cost implication. Conclusions: Therapies for chronic HCV have evolved dramatically in recent years. Interferon-free regimens are now possible without compromise in the rate of sustained viral response. The decision as to which regimen is most appropriate is multifactorial, and based on efficacy, safety and cost.",
    author = "Miller, {M. H.} and K. Agarwal and A. Austin and A. Brown and Barclay, {S. T.} and P. Dundas and Dusheiko, {G. M.} and Foster, {G. R.} and R. Fox and Hayes, {P. C.} and C. Leen and C. Millson and Ryder, {S. D.} and J. Tait and A. Ustianowski and Dillon, {J. F.}",
    year = "2014",
    month = "6",
    doi = "10.1111/apt.12764",
    language = "English",
    volume = "39",
    pages = "1363--1375",
    journal = "Alimentary Pharmacology & Therapeutics",
    issn = "0269-2813",
    publisher = "Wiley",
    number = "12",

    }

    Miller, MH, Agarwal, K, Austin, A, Brown, A, Barclay, ST, Dundas, P, Dusheiko, GM, Foster, GR, Fox, R, Hayes, PC, Leen, C, Millson, C, Ryder, SD, Tait, J, Ustianowski, A & Dillon, JF 2014, 'Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy', Alimentary Pharmacology & Therapeutics, vol. 39, no. 12, pp. 1363-1375. https://doi.org/10.1111/apt.12764

    Review article : 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy. / Miller, M. H. (Lead / Corresponding author); Agarwal, K.; Austin, A.; Brown, A.; Barclay, S. T.; Dundas, P.; Dusheiko, G. M.; Foster, G. R.; Fox, R.; Hayes, P. C.; Leen, C.; Millson, C.; Ryder, S. D.; Tait, J.; Ustianowski, A.; Dillon, J. F.

    In: Alimentary Pharmacology & Therapeutics, Vol. 39, No. 12, 06.2014, p. 1363-1375.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Review article

    T2 - 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy

    AU - Miller, M. H.

    AU - Agarwal, K.

    AU - Austin, A.

    AU - Brown, A.

    AU - Barclay, S. T.

    AU - Dundas, P.

    AU - Dusheiko, G. M.

    AU - Foster, G. R.

    AU - Fox, R.

    AU - Hayes, P. C.

    AU - Leen, C.

    AU - Millson, C.

    AU - Ryder, S. D.

    AU - Tait, J.

    AU - Ustianowski, A.

    AU - Dillon, J. F.

    PY - 2014/6

    Y1 - 2014/6

    N2 - Background: Therapeutic options for the management of hepatitis C virus (HCV) infection have evolved rapidly over the past two decades, with a consequent improvement in cure rates. Novel therapeutic agents are an area of great interest in the research community, with a number of these agents showing promise in the clinical setting. Aims: To assess and present the available evidence for the use of novel therapeutic agents for the treatment of HCV, updating previous guidelines. Methods: All Phase 2 and 3 studies, as well as abstract presentations from international Hepatology meetings were identified and reviewed for suitable inclusion, based on studies of new therapies in HCV. Treatment-naïve and experienced individuals, as well as cirrhotic and co-infected individuals were included. Results: Sofosbuvir, simeprevir and faldaprevir, along with pegylated interferon and ribavirin, have a role in the treatment of chronic HCV infection. The precise regimens are largely dependent on the patient characteristics, patient and physician preferences, and cost implication. Conclusions: Therapies for chronic HCV have evolved dramatically in recent years. Interferon-free regimens are now possible without compromise in the rate of sustained viral response. The decision as to which regimen is most appropriate is multifactorial, and based on efficacy, safety and cost.

    AB - Background: Therapeutic options for the management of hepatitis C virus (HCV) infection have evolved rapidly over the past two decades, with a consequent improvement in cure rates. Novel therapeutic agents are an area of great interest in the research community, with a number of these agents showing promise in the clinical setting. Aims: To assess and present the available evidence for the use of novel therapeutic agents for the treatment of HCV, updating previous guidelines. Methods: All Phase 2 and 3 studies, as well as abstract presentations from international Hepatology meetings were identified and reviewed for suitable inclusion, based on studies of new therapies in HCV. Treatment-naïve and experienced individuals, as well as cirrhotic and co-infected individuals were included. Results: Sofosbuvir, simeprevir and faldaprevir, along with pegylated interferon and ribavirin, have a role in the treatment of chronic HCV infection. The precise regimens are largely dependent on the patient characteristics, patient and physician preferences, and cost implication. Conclusions: Therapies for chronic HCV have evolved dramatically in recent years. Interferon-free regimens are now possible without compromise in the rate of sustained viral response. The decision as to which regimen is most appropriate is multifactorial, and based on efficacy, safety and cost.

    UR - http://www.scopus.com/inward/record.url?scp=84898722811&partnerID=8YFLogxK

    U2 - 10.1111/apt.12764

    DO - 10.1111/apt.12764

    M3 - Article

    VL - 39

    SP - 1363

    EP - 1375

    JO - Alimentary Pharmacology & Therapeutics

    JF - Alimentary Pharmacology & Therapeutics

    SN - 0269-2813

    IS - 12

    ER -